Search the Newsreel

China Medical System: Innovative products fueled double-digit growth, with strong R&D and global expansion momentum

Why Medicenna Therapeutics Corp stock surged yesterday

Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)?

Globus Medical (GMED) reported second-quarter 2026 results with increased sales but a decline in net income and EPS, reaffirming its full-year revenue outlook. The company's investment case hinges on translating revenue growth into durable profits amidst integration and cost control challenges from acquisitions. While …

Resilient Fresenius Medical Care stock holds its ground as dividend and consensus support valuation

Fresenius Medical Care (FMS) stock closed at $23.75 on August 14, 2026, near the analyst consensus price target of $23.57, suggesting a fair valuation. The company offers an annual dividend of $0.61 per share, translating to a 2.57% yield with a payout ratio of …

Medical Properties Trust, Inc. Stock 12‑Month Price Target Cut to $5.11, Implies 22% Upside

Medical Properties Trust, Inc. (MPT) has seen its average 12-month price target reduced from $5.21 to $5.11 by analysts, with a range of $4.25 to $7 per share. This new target suggests a potential 22% upside from its August 14th closing price. The consensus …

Prajay Engineers Q1 Results: Net loss narrows to ₹237.9 lakh

IceCure Medical (NASDAQ: ICCM) director lists no shares

IceCure Medical Ltd. director David Salton filed an initial Form 3, reporting his status as a director of the company. This filing indicates no specific equity holdings, derivative positions, or transactions at this time, meaning David Salton does not currently report any direct or …

IceCure Medical : Initial Statement of Beneficial Ownership (Form 3)

This article reports that IceCure Medical (ICCM) director, David Salton, filed an Initial Statement of Beneficial Ownership of Securities (Form 3) with the SEC on August 17, 2026. This form indicates that Salton became a reporting person on August 12, 2026, due to his …

IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake

IceCure Medical Ltd. (NASDAQ: ICCM) has granted 73,890 restricted share units (RSUs) to its VP Human Resources, Dotan Merav Nir, as a compensation-related equity award on August 14, 2026. This grant increases his total holdings to 76,168 ordinary shares and RSUs. The new RSUs …

IceCure Medical (ICCM) director Chan Vincent leaves board

IceCure Medical Ltd. (ICCM) director Chan Vincent Chun Hung has ceased serving on the board as of August 12, 2026. This departure means he is no longer subject to Section 16 reporting obligations, and no insider transactions were reported in connection with his exit. …

IceCure Medical (NASDAQ: ICCM) awards CFO 181K stock units at $0

IceCure Medical Ltd.'s CFO, Meir Peleg, was granted 181,483 restricted share units (RSUs) on August 14, 2026, at a price of $0.00 per share-equivalent. These RSUs have a vesting schedule where 25% vest on August 11, 2027, and the remaining 75% vest in twelve …

APYX Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprise Reaches 16.27% - Earnings Call Highlights

Profound Medical (NASDAQ: PROF) targets higher TULSA throughput

Profound Medical Corp. (NASDAQ: PROF) has introduced new real-time interventional MRI Treatment Delivery Consol (TDC) software for its TULSA-PRO® prostate ablation platform. This software aims to enhance procedural efficiency and physician experience, potentially increasing the number of TULSA Procedures™ per system per day from …

Some physicians report four TULSA procedures a day—what changes next?

Profound Medical (NASDAQ: PROF) has introduced new Treatment Delivery Consol (TDC) software for its TULSA-PRO® platform, aiming to increase procedural efficiency and allow surgeons to perform up to six TULSA Procedures™ per day. The upgrade enhances real-time interventional MRI control and physician-requested interface improvements, …

Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths

CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital International (MSCI). The change …

BofA Securities Adjusts Medical Properties Trust Price Target to $4.25 From $5

BofA Securities has revised its price target for Medical Properties Trust (MPT) to $4.25, down from $5.00. This adjustment comes shortly after MPT announced it would maintain its quarterly dividend at $0.09 per share and completed a $2.4 billion note issuance for debt refinancing. …

Vivani Medical posts slide presentation under Reg FD; Exhibit 99.1 attached

Vivani Medical has filed an 8-K report, attaching a slide presentation as Exhibit 99.1. This presentation was distributed to the investment community and at conferences, providing key information about the company. The company notes that the presentation reflects information only as of the filing …

Form 8K PROFOUND MEDICAL CORP. For: 17 August By Investing.com

The article reports that Profound Medical Corp. filed a Form 8K on August 17. This filing is a standard requirement for public companies to announce major events that shareholders should know about. No specific details about the content of the 8K are provided in …

Themis Medicare updates Company Secretary and RTA contact emails

Medical Developments International Firms Ahead of FY26 Results — Is Penthrox Turnaround Finally Taking Hold?

Profound Medical (PROF) shifts CFO, ex-finance chief stays on as paid adviser

Profound Medical Corp. (PROF) has appointed Matthew Sobczyk as Interim Chief Financial Officer, effective August 14, 2026, following the resignation of Rashed Dewan. Dewan will receive a severance package and will provide transition and advisory services as a paid consultant until November 25, 2026. …

NeuroOne Medical (NMTC) Advances 6% to $1.94, Approaching Key Resistance - RSI Oversold Picks

AVNS Q1 2026 Earnings: EPS Beats Estimates by 54%, Revenue Data Not Disclosed - Earnings Sentiment Score

Raymond James raises Praxis Precision Medicines price target on pipeline outlook

Raymond James has increased its price target for Praxis Precision Medicines Inc. (NASDAQ:PRAX) shares from $765 to $945, maintaining a Strong Buy rating. This upgrade is driven by an increased probability of success for the company's EMERALD trial and higher peak sales forecasts for …

Star Sports Medicine Co: Revenue up 21.6% and adjusted profit up 24.3%, driven by strong global expansion

Medicamen Biotech Ltd Falls to 52-Week Low of Rs 214.9 as Sell-Off Deepens

RCEL Q2 2026 Earnings: Narrower Quarterly Loss Beats Estimates; Shares Slip 2% - Earnings Quality Analysis

Star Sports Medicine Boosts Revenue but Sees Interim Profit Decline on Higher Costs

62,072 Shares in DICK'S Sporting Goods, Inc. $DKS Bought by SCS Capital Management LLC

SCS Capital Management LLC has acquired 62,072 shares of DICK'S Sporting Goods, Inc. (NYSE:DKS), valued at approximately $14.1 million, representing 0.07% of the company's stock. Other institutional investors have also significantly increased their holdings in DKS. Analysts maintain a "Moderate Buy" rating for DICK'S …

Medicamen Biotech Ltd. Share Price Fall: Stock Analysis

Raily Aesthetic Medicine Sets Board Meeting to Review Interim Results and Dividend

ETFs Investing in Seach Medical Group Ltd. Stocks

Guanze Medical to Review 2026 Interim Results and Consider Dividend at August Board Meeting

SBC Medical (SBC) Q2 Revenue Beats Estimates; Valuation Remains Unclear Amid GF Score™ Challenges

522,900 Shares in Treace Medical Concepts, Inc. $TMCI Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC acquired 522,900 shares of Treace Medical Concepts, Inc. ($TMCI) in the first quarter, valued at approximately $701,000, giving them a 0.81% stake. Other institutional investors also adjusted their holdings, with hedge funds and institutions collectively owning 84.08% of the company. Despite …

OncoSil Medical (ASX:OSL) Shares Fall 7.5% as FDA Window Elapses